Literature DB >> 7911457

Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle.

K L Donaldson1, G L Goolsby, A F Wahl.   

Abstract

The overt effects of the anti-cancer drugs cisplatin (cis-DDP) and taxol appear to be DNA modification and microtubule stabilization respectively, yet the mechanisms by which these drugs elicit tumor cell death are not well understood. In this report cell sensitivities to cis-DDP and taxol were accurately determined as a function of cell proliferation and cell cycle stage. Quiescent fibroblasts restimulated to synchronously enter the cell cycle become maximally sensitive to cis-DDP immediately preceding DNA synthesis, and resistance increases with onset of DNA synthesis. Mid-log proliferating cells were separated into progressive stages of the cell cycle by centrifugal elutriation or by double thymidine (dThd) block. Cells staged by either method are maximally sensitive to cis-DDP in G1, just prior to the onset of DNA synthesis and minimally sensitive in peak DNA synthesis, with entry into S phase resulting in a 2-fold decrease in sensitivity. Cells that remained blocked at the G1/S phase boundary during cis-DDP treatment remain maximally sensitive after release. Sensitivity to taxol increases at 2 points: transiently during transition of normal cells from quiescence to proliferation and steadily as proliferating cells progress from early G1 to late G2. This 3-fold increase in taxol sensitivity through the cell cycle is rapidly reversed upon cell division. Synchronous cells treated with either drug at points of maximum sensitivity initiate apoptotic DNA fragmentation 12-14 hr post-exposure to drug.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911457     DOI: 10.1002/ijc.2910570614

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

Review 1.  Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.

Authors:  G Pentheroudakis; E Razis; A Athanassiadis; N Pavlidis; G Fountzilas
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

3.  E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis.

Authors:  J Nip; D K Strom; B E Fee; G Zambetti; J L Cleveland; S W Hiebert
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

4.  p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells.

Authors:  Lauren Marquis; Mai Tran; Woonyoung Choi; I-Ling Lee; Dennis Huszar; Arlene Siefker-Radtke; Colin Dinney; David J McConkey
Journal:  Cancer Biol Ther       Date:  2012-05-01       Impact factor: 4.742

5.  Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors.

Authors:  N J Millenbaugh; Y Gan; J L Au
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

6.  Naturally occurring resistance of bone marrow mononuclear and metastatic cancer cells to anticancer agents.

Authors:  Christina Richard; Jonathan Yau; John P H Th'ng; Wilhelmina C M Duivenvoorden
Journal:  Clin Exp Metastasis       Date:  2006-11-03       Impact factor: 5.150

7.  TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status.

Authors:  Marta Herreros-Villanueva; Pilar Muñiz; Carlos García-Girón; Mónica Cavia-Saiz; María J Coma del Corral
Journal:  J Transl Med       Date:  2010-02-10       Impact factor: 5.531

8.  Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival.

Authors:  Jill M Wagner; Larry M Karnitz
Journal:  Mol Pharmacol       Date:  2009-04-29       Impact factor: 4.436

Review 9.  Nephronophthisis: should we target cysts or fibrosis?

Authors:  Gisela G Slaats; Marc R Lilien; Rachel H Giles
Journal:  Pediatr Nephrol       Date:  2015-07-29       Impact factor: 3.714

10.  New insights into the kinetic resistance to anticancer agents.

Authors:  B Chauffert; M T Dimanche-Boitrel; C Garrido; M Ivarsson; M Martin; F Martin; E Solary
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.